Editors' picks from other sources

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
New and experimental hepatitis C treatment
Who will win the hepatitis C market?

Could approval of the Merck and Vertex hepatitis C protease inhibitors stymie development of many other HCV drugs in the pipeline, by making trial design and recruitment more difficult?

Published
15 March 2011
From
Seeking Alpha
New and experimental hepatitis C treatment
The Hepatitis C Pipeline Report

The Hepatitis C Treatment Pipeline Report by Tracy Swan reviews the latest in hepatitis C treatment and diagnostics.

Published
09 March 2011
From
Treatment Action Group
Hepatitis C treatment
Hep C Treatment Telaprevir Gets Fast-Tracked FDA Review

Vertex Pharmaceuticals announced on January 20 that the U.S. Food and Drug Administration (FDA) has agreed to expedite its approval review of the experimental hepatitis C protease inhibitor telaprevir. The agency has until May 23—six months from the original New Drug Application (NDA) filing date of November 23—to complete its review.

Published
21 January 2011
From
AIDSMeds
New and experimental hepatitis C treatment
Investigational drug for hepatitis C boceprevir achieved significantly higher sustained virologic response rates compared to control

Merck reported today that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor.

Published
31 October 2010
From
Digital Journal
New and experimental hepatitis C treatment
Vertex releases results of phase III study of telaprevir in hepatitis C

Vertex Pharmaceuticals today announced results from the Phase 3 ILLUMINATE study, which was designed to evaluate whether there was any benefit to extending therapy from 24 to 48 weeks in people whose hepatitis C virus (HCV) was undetectable at weeks 4 and 12 of treatment (extended rapid viral response or eRVR).

Published
10 August 2010
From
Business Wire
← Prev1...1819202122Next →

Filter by country